The Claim
In adults with type 2 diabetes, administration of liraglutide at a dose of 0.6 mg/day does not result in a statistically significant reduction in incremental postprandial glucose excursions over a five-hour period, indicating that a threshold dose is required for glucose-lowering efficacy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, taking 0.6 mg of liraglutide per day does not lower blood sugar levels after meals more than would be expected by chance, and higher doses are needed to achieve a measurable effect.
See the scientific wording
In adults with type 2 diabetes, the lowest dose of liraglutide (0.6 mg/day) does not produce a statistically significant reduction in incremental postprandial glucose excursions over five hours, suggesting a threshold effect for glucose-lowering efficacy that requires higher doses.
Liraglutide binds to receptors in the pancreas and stomach, causing the pancreas to release more insulin after meals and slowing down how fast food leaves the stomach. This dual action lowers the spike in blood sugar after eating, but only when enough liraglutide is present to trigger both effects strongly.
What the research says
1 studyThe study found that the smallest dose of liraglutide (0.6 mg) didn’t significantly lower blood sugar spikes after meals, but higher doses did. This means you need more than the lowest dose to really control post-meal sugar spikes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.